Roivant Discovery Business Development seeks to identify collaborative opportunities that will create value for our partners and patients. Specifically, we are looking to partner on discovery-stage small molecule drug candidates from biotechnology and pharmaceutical companies, and academic institutions.
Ideal programs would have the following general characteristics:
- Small molecule program directed to a validated biological target or pathway
- Potential to be first-in-class and/or best-in-class
- Amenable to structure-based drug design
- In the hit-to-lead or lead optimization stage of discovery